Research and Development
This group unites PF patients, caregivers, researchers and medical professionals in a platform to... View more
Organizer:
- Organized by
-
-
Reviva’s Investigational Therapy RP5063 Receives FDA Orphan Drug Status for IPF Treatment
-
Reviva’s Investigational Therapy RP5063 Receives FDA Orphan Drug Status for IPF Treatment
The U.S. Food and Drug Administration recently granted orphan drug status to Reviva Pharmaceuticals’ treatment candidate RP5063 for idiopathic pulmonary fibrosis (IPF).
Reviva is now planning to launch Phase 2 studies testing RP5063 in both IPF and pulmonary arterial hypertension (PAH) patients. The FDA granted orphan drug designation to the therapy in 2016 for the treatment of PAH.
“Obtaining the orphan drug designation is a significant regulatory milestone as well as a notable achievement for Reviva, since it validates the significant therapeutic potential of RP5063 for the treatment of IPF,” Laxminarayan Bhat, PhD, founder, president and CEO of Reviva, said in a press release.
Read more about this news here: “Reviva’s Investigational Therapy RP5063 Receives FDA Orphan Drug Status for IPF Treatment“
-
0 Replies
Sorry, there were no replies found.
Log in to reply.